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Globally, end-stage kidney disease (ESKD) is a huge burden on health care systems. The aims of this study were to perform a
comprehensive epidemiological and etiological report of ESKD patients commencing RRT in Oman with an emphasis on genetic
causes and inherited kidney disease. All newly registered Omani patients with ESKD commencing RRT from 2001 until 2015 (𝑛 =
2,922) were analysed using the RRT register in Oman. All potentially genetic or inherited causes of ESKDwere reviewed. In Oman,
ESKD ismore prevalent inmales (57.1%) than females (42.9%)with amedian age of incident ESKDof 53 years.Diabetic nephropathy
was themost prevalent cause of ESKD (46%), followed by hypertensive nephropathy (19%), glomerulonephritis (15%), and inherited
kidney disease (5%). For patients less than 20 years of age inherited kidney disease accounted for 32.5% of cases. Of this cohort with
inherited renal disease, 40.3% had autosomal dominant polycystic kidney disease, 11.5% had congenital anomalies of the kidney
and urinary tract, 9.4% had Alport syndrome, and 7.2% had autosomal recessive polycystic kidney disease. This study represents a
comprehensive population-based epidemiological and etiological report of ESKD patients in Oman commencing RRT. Inherited
kidney disease was the leading cause of paediatric ESKD.
1. Introduction
Chronic kidney disease (CKD) is a common condition
characterized by irreversible kidney damage and reduced
glomerular filtration rates that may progress to end-stage
kidney disease (ESKD), where renal replacement therapy
(RRT) is necessary for long term survival. The number of
patients receiving RRTworldwide in 2010 was estimated to be
2.6 million, whereas the estimated number of actual patients
demanding RRT was 4.9 million [1]. This RRT gap is one
of the global challenges presented with the growing rate of
ESKD.
Inherited kidney diseases are important causes of mor-
bidity and may lead to both progressive CKD and ESKD.
Inherited kidney disease accounts for approximately 20%
of all CKD cases and is an important cause of ESKD [2].
Renal registry studies suggest that at least 10% of ESKD in
adults is related to inherited renal disease, with autosomal
dominant polycystic kidney disease (ADPKD)making a large
proportion of these cases [3]. In the United States (US) and
Europe, congenital anomalies of the kidney and urinary tract
(CAKUT) and inherited nephropathies are the major causes
of CKD among youngest ESKD groups [4]. The situation in
theMiddle East countries was revealed to be the same, but the
prevalence of inherited kidney disease is reported to bemuch
higher (up to 30%) compared to Europe due to high rates of
consanguinity [4].
Oman is the second largest country in the South East
of Arabian Peninsula (309,500 square kilometres) with a
relatively small and young population (3,831,553 people). In
Oman, there has been a progressive increase in the ESKD
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incidence and prevalence over the last three decades [5]. The
incidence rate of ESKD patients receiving RRT in Oman at
the end of 1998was 21 permillion population (PMP), whereas
the calculated incidence in 2013 was 120 PMP [5]. Along with
the increasing rate of ESKD, a gradual increase in morbidity
caused by CKD had been observed.
Ministry of Health data from Oman reports that 39%
of perinatal deaths in hospitals are associated with con-
genital malformations and genetic disorders [6] and the
consanguinity rates were found to be higher (73%) between
parents of newborns with major congenital malformations
[7]. The prevalence of some rare inherited kidney diseases
such as cystinuria and autosomal recessive polycystic kidney
disease (ARPKD) was reported to be higher compared to
the worldwide prevalence due to high consanguinity [8, 9].
However, there is no comprehensive data estimating the
magnitude of inherited kidney disease in patients in Oman.
Here we review ESKD patients commencing RRT in Oman
over a fifteen-year period and report the proportion and
clinical characteristics of congenital and inherited kidney
disease.
2. Materials and Methods
2.1. Ethical Approvals. This study is part of an original
research titled “Genetic Studies of Inherited Kidney Disease
in Oman,” which was ethically approved by the Research
and Ethical Review and Approval Committee, Ministry of
Health (MH/DGP/R&S/PROPOSAL_APPROVED/18/2014),
and by the Ethics Committee, College ofMedicine andHealth
Sciences, Sultan Qaboos University (MREC #1096).
2.2. Retrospective Analysis. Data from newly registered
Omani patients with ESKD commencing RRT from 2001 to
2015 was analysed using renal replacement therapy register
in Oman. The registry contains baseline characteristics of
patients at initiation of RRT and updates until patient
death. The baseline characteristic information included is
sex, comorbid conditions (including diabetesmellitus, hyper-
tension, ischemic heart disease, cerebrovascular disease, and
respiratory disease), family history of disease, initial hyper-
tension medications, and initial pre-RRT BMI, serum albu-
min, and creatinine. Haemodialysis data, peritoneal dialysis
data, and renal transplantation data were also included in
the registry. This data is completed by nephrologists in all
renal dialysis units throughout the country once the patient
reached ESKD using a standardized form and sent to the
main renal dialysis unit in Muscat, where the RRT registry
is maintained in a comprehensive database [5]. The registry
data collection in Oman has been standardized as much as
possible to allowmeaningful comparisons to other countries.
The data set collected is similar to that collected by the
USRDS (form 2728) [5].
All potentially congenital, genetic, or hereditary causes of
kidney diseases were extracted from the registry within the
study period according to the coding protocol of this registry.
Cases registered and classified under the code Hereditary
Familial Renal Disease (HFRD) were reviewed. This code
includes the majority of inherited kidney diseases includ-
ing ADPKD, ARPKD, Alport syndrome, primary hyperox-
aluria, cystic dysplastic kidney, nephronophthisis, Bartter
syndrome, and inherited renal tubular acidoses. The propor-
tion of inherited kidney disease among those commencing
RRT was calculated. Statistical analysis was performed using
IBM SPSS Statistics 20.
3. Results and Discussion
3.1. Characteristics of ESKD Patients Commencing RRT in
Oman. From 2001 to 2015, a total of 2,922 new patients
commenced RRT due to different causes. Males contributed
57.1% (𝑛 = 1668) of the patients and females contributed
42.9% (𝑛 = 1254). The mean age of RRT commencement
was 50.14 ± SD 17.5 years, while the median age was 53 years.
Overall, 1321 (47.1%) cases of ESKD occurred among patients
who were 45–64 years, whereas 884 (31.5%) occurred among
patients who were ≤44 years and 599 (21.2%) in patients who
were 65 years and over (Figure 1(a)).
Diabetic nephropathy was the most prevalent cause of
ESKD (46%), followed by hypertensive nephropathy (HTN)
(19%) and chronic glomerulonephritis (CGN) (15%) (Fig-
ure 1(c)). Inherited kidney disease contributed just 5% of
the total RRT population. Other aetiologies, such as uro-
logical, tubulointerstitial kidney disease and vascular causes,
comprised 11% of RRT population. However, a dramatically
different picture was revealed when the primary diagnosis is
given by age groups (Tables 1 and 2). In patients less than 20
years of age, inherited kidney disease was the most common
primary cause of kidney disease (Table 1) accounting for 42%
of ESRD in 0–12 years’ age group and 27% of ESRD in the
13–19 years’ age group (Table 2). Therefore, in patients less
than 20 years of age inherited kidney disease accounted for
62 of 200 cases (32.5%) of ESRD. A comparison of Omani
registry data from comparator countries shows a much
smaller burden of ADPKD in Oman (just 2%) than Western
countries (Table 3). The reasons for this probably reflect the
relative young population in Oman. An age comparison of
the total population of Omani versus age of ESKD population
confirms this (Figures 1(a) and 1(b)). Published data from
Australia and New Zealand describe an increase in the
contribution of ADPKD to ESRD over the last 5 decades [15]
and reflect an overall increase in age of the ESRD population.
Similar observations have been made in other countries
includingDenmark [16] and theUSA [17].Thus, over the next
few decades the relative contribution of ADPKD to ESRD in
Oman will likely increase towards 5–10%.
3.2. Characteristics of Inherited Kidney Disease Patients on
ESKD. The distribution of males with inherited kidney dis-
ease was found to be higher (𝑛 = 79; 56.8%) than females (𝑛 =
60; 43.2%). Patients with inherited kidney disease started
RRT at a younger age with a mean of 29.4 ± SD 20.1 and
median age of 21 years (Figure 1(d)). A positive family history
of inherited kidney disease was present in 36.7% of inherited
kidney disease cases. Dialysis was the initial RRT modality
in all inherited kidney disease patients (𝑛 = 115) except 24
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Figure 1: Characteristics of ESKD patients commencing RRT in Oman. (a) Percentage age distribution of patients with ESKD. (b) Percentage
age distribution of Omani population (2014 data). (c) Aetiology of ESKD in Oman. (d) Comparison of percentage of patients with hereditary
kidney disease (HKD) and nonhereditary kidney disease (non-HKD) across age groups.
Table 1: Distribution of primary kidney diagnosis by age in ESKD patients (2001–2015).
Primary causes of end-stage kidney disease
Age group
(years)
Diabetic
nephropathy
Hypertensive
nephropathy Glomerulonephritis
Inherited
kidney disease Other
Uncertain
aetiology Total
𝑁 % 𝑁 % 𝑁 % 𝑁 % 𝑁 % 𝑁 % 𝑁 %
0–12 2 0.1 0 0 16 0.6 30 1.1 15 0.5 8 0.3 71 2.5
13–19 0 0 4 0.1 45 1.6 35 1.2 33 1.2 12 0.4 129 4.6
20–44 173 6.2 125 4.5 187 6.7 33 1.2 119 4.2 47 1.7 684 24.4
45–64 769 27 253 9 139 5 36 1.3 77 2.7 47 1.7 1321 47.1
65–74 259 9.2 110 3.9 27 1 1 0 36 1.3 7 0.2 440 15.7
≥75 73 2.6 49 1.7 10 0.4 4 0.1 19 0.7 4 0.1 159 5.7
Total 1276 45.5% 541 19.3% 424 15.1% 139 5% 299 10.6% 125 4.5% 2804 100%
Percentages calculated after excluding patients without primary diagnosis data.
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Table 2: Distribution of inherited kidney disease by age in ESKD patients (2001–2015).
Age group (years) Inherited kidney disease Remaining causes Total
𝑁 % 𝑁 % 𝑁
0–12 30 42.3 41 57.7 71
13–19 35 27.1 94 72.9 129
20–44 33 4.8 651 95.2 684
45–64 36 2.7 1285 97.3 1321
65–74 1 0.2 439 99.8 440
≥75 4 2.5 155 97.5 159
Total 139 5 2665 95 2804
Table 3: Primary causes of ESKD in Oman and other countries.
Country Diabetic Hypertension Glomerulonephritis Uncertain aetiology ADPKD Reference
Jordan 29.2 14.2 12.3 12.4 — [10]
United Kingdom 15.9 6.1 19 16 9.9 [11]
Libya 26.5 14.6 21.2 10.2 6.3 [12]
India 20.5 4.5 34.5 19 5 [13]
Pakistan 10 12 37 19 3 [13]
Turkey 29.9 25.9 7.9 15.7 3.8 [14]
Oman 45.5 19.3 15.1 4.5 2 This study
patients, who received preemptive transplant in the form of
living-related donor (𝑛 = 6) and living nonrelated donor (𝑛 =
18) (Table 4). Currently, in the cohort of inherited kidney
disease patients, 37% have a functioning transplant, 38% are
receiving haemodialysis, and 3.6% are receiving peritoneal
dialysis (Table 4). A total of 25 patients (18%) have died during
the study period with cardiac disease being the leading cause
of death.Hypertensionwas themost common comorbidity in
inherited kidney disease patients at initiation of RRT (54.7%),
compared to diabetes (2.2%), ischemic heart disease (3.6%),
cerebrovascular diseases (1.4%), and respiratory diseases
(1.4%) (Table 4). ADPKD was the most common inherited
kidney disease diagnosis, accounting for 40.3% of cases,
followed by CAKUT (11.5%), Alport syndrome (9.4%), and
ARPKD (7.2%) (Table 5).
This study represents a comprehensive, up-to-date
population-based epidemiological and etiological report of
Oman patients reaching ESKD and commencing RRT. It
reveals that ESKD is more prevalent in males, with a ratio
of 1.3, which is consistent with data reported from other
countries [18]. The median age of incident ESKD patients
starting RRT was 53 years and is in agreement with that
reported in other Middle East countries with almost similar
demographics and socioeconomic features, including Saudi
Arabia [19] and Jordan [10], but substantially lower than that
reported in European countries, including United Kingdom
(UK) [11], Croatia, Georgia and Cyprus [20], and the US [21].
The data we present here from Oman shows that there is a
sharp increase in the prevalence of ESKD with increasing
age. We anticipate that as the population ages in Oman, the
ESKD prevalence will increase. This trend is consistent with
that reported from Saudi Arabia, which is comparable to the
situation in developed countries where the rate of elderly is
recently decreased or stabilized [19].
Diabetic nephropathy was the commonest underlying
cause of ESKD and was more prevalent among older patients
of 45 years and over. Eighteen years ago, the prevalence of
diabetic nephropathy among RRT patients in Oman was
reported to be 14.5% [22], whereas in our study it accounted
for 45.5%of ESKDpopulation.Theobserved incidence of dia-
betic nephropathy leading to ESKD places Oman among the
highest countries in the world. Table 3 allows a comparison
in the percentage of incident ESKD patients due to diabetes
mellitus in Oman and other countries.
In this study, we described for the first time the preva-
lence of inherited kidney disease causing ESKD in Oman.
Inherited kidney disease comprises 5% of all causes of ESKD
but was highly prevalent in paediatric ESKD patients. The
detected prevalence of hereditary kidney disease in our
study is considerably lower than that reported in other
countries including Libya (12%) [10] andAustralia (10%) [23];
however, it is consistent with the summarized estimate of
the countries of the Gulf Cooperation Council (GCC) of
4.43% [24]. Nonetheless, inherited and congenital kidney
disease is thought to be an important aetiology of ESKD
in Omani population in which the consanguinity rate is
relatively high (56.3%) [25]. The detected low frequencies
International Journal of Nephrology 5
Table 4: Comparison between ADPKD and other causes of hereditary kidney disease.
ADPKD Other inherited kidneydiseases
Total inherited kidney
disease population
𝑁 % 𝑁 % 𝑁 %
Positive family history of disease 23 41 28 33.7 51 37
Comorbidity
Diabetes mellitus 2 3.6 1 1.2 3 2.2
Hypertension 34 61 42 50.6 76 55
Ischemic heart disease 5 8.9 0 0 5 3.6
Cerebrovascular disease 1 1.8 1 1.2 2 1.4
Respiratory disease 1 1.8 1 1.2 2 1.4
Other 6 11 17 20.5 23 17
First RRT modality 0
Haemodialysis 42 75 63 75.9 105 76
Peritoneal dialysis 1 1.8 9 10.8 10 7.2
preemptive transplant, living related donor 1 1.8 5 6.02 6 4.3
preemptive transplant, living nonrelated donor 12 21 6 7.23 18 13
Current status
Haemodialysis 18 32 35 40.7 53 38
Peritoneal dialysis 1 1.8 4 4.65 5 3.6
Transplant 22 39 30 34.9 52 37
Lost to follow-up 2 3.6 1 1.16 3 2.2
Deceased 13 23 12 14 25 18
Cause of death
Cardiac disease 5 38 3 25 8 32
Cerebrovascular disease 2 15 1 8.33 3 12
Infection 3 23 2 16.7 5 20
Other 1 7.7 4 33.3 5 20
Uncertain 2 15 2 16.7 4 16
of inherited kidney disease are expected to be due to high
mortality rate among newborns with recessively inherited
kidney disorders. CKD in paediatric patients is a devastating
illness and the mortality rate for those with ESKD receiving
RRT is expected to be 30–150 times higher when compared to
a general paediatric population [26]. Moreover, since what is
seen from ESKD is only the “tip of the iceberg” of CKD we
expect inherited kidney disease patients with earlier stages
of CKD are probably exceeding those reaching ESRD. At
present, there are no means to capture this important data.
As expected, ADPKD was the most prevalent inherited
kidney disease, accounting for 2% of total ESKD population.
This prevalence is substantially lower than that reported in
developed countries including the UK (9.9%) [11] and lower
than the summarized estimate of ADPKD in GCC countries
(4.8%), likely reflecting a younger ESKD population inOman
[24].
4. Conclusions
In summary, this study represents a population-based etio-
logical report of Omani ESKD commencing RRT from 2001
to 2015. It clearly shows that Oman is facing major factors
that globally are fundamentally responsible for the growing
incidence of ESKD in adults, namely, an aging population
and a high burden of diabetes mellitus. Therefore, health
care providers must concentrate on strategic actions that
highlight primary prevention, early detection, and dynamic
management ofCKDpopulation. For the first time, the preva-
lence of inherited kidney disease causing ESKD in Oman has
6 International Journal of Nephrology
Table 5: Inherited kidney diseases in ESKD population (2001–2015).
Inherited kidney disease Number Proportion of inheritedkidney disease (%)
Proportion of ESRD
in this cohort (%)
Age group (𝑁)
0–12 13–19 20–44 45+
Autosomal dominant
polycystic kidney disease
(ADPKD)
56 40.3 2 1 1 17 37
Congenital anomalies of
kidney and urinary tract
(CAKUT)
16 11.5 0.6 8 6 2 0
Alport syndrome 13 9.4 0.5 0 7 6 0
Autosomal recessive
polycystic kidney disease
(ARPKD)
10 7.2 0.4 3 6 0 1
Dysplastic cystic kidney 7 5 0.2 1 3 2 1
Steroid resistant nephrotic
syndrome (congenital &
childhood)
5 3.6 0.2 4 1 0 0
Primary hyperoxaluria 5 3.6 0.2 2 2 1 0
Prune-belly syndrome 5 3.6 0.2 2 2 1 0
Familial focal segmental
glomerulosclerosis 5 3.6 0.2 1 2 2 0
Medullary cystic kidney 4 2.9 0.1 3 0 1 0
Familial interstitial
nephropathy 2 1.4 0.1 1 1 0 0
Haemolytic uremic
syndrome 2 1.4 0.1 2 0 0 0
Mesangioproliferative
glomerulosclerosis 2 1.4 0.1 0 1 1 0
Membranoproliferative
glomerulosclerosis 2 1.4 0.1 0 0 0 2
Nephronophthisis 1 0.7 0 1 0 0 0
Bartter syndrome 1 0.7 0 0 1 0 0
Lowe's syndrome 1 0.7 0 0 1 0 0
Renal tubular acidosis 1 0.7 0 0 1 0 0
Undetermined familial
disease 1 0.7 0 1 0 0 0
Total 139 100% 5% 30 35 33 36
been accurately described and this data emphasizes need to
measure the frequencies of inherited kidney disease patients
in earlier stages of CKD and assess their rate of progression
to ESKD.
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